1 395例不同类型恶性肿瘤患者弓形虫感染的血清流行病学调查

陈跃琴; 夏建萍; 钱春艳

doi:10.19428/j.cnki.sjpm.2019.19925

1 395例不同类型恶性肿瘤患者弓形虫感染的血清流行病学调查

Sero-epidemiological survey on Toxoplasma gondii infections among 1 395 patients with various types of cancers

摘要

摘要:
目的了解不同类型恶性肿瘤患者的弓形虫感染情况，为恶性肿瘤患者弓形虫感染防控提供参考依据。
方法对2012-2019年在杭州市余杭区第一人民医院接受治疗的1 395例恶性肿瘤患者（肺癌410例，肝癌370例，口腔癌115例，宫颈癌320例，白血病180例）以及在杭州市余杭区第一人民医院体检中心接受健康体检的300例健康者，采用酶联免疫吸附试验进行血清抗弓形虫IgG和IgM抗体检测，比较不同类型恶性肿瘤患者以及不同特征恶性肿瘤患者弓形虫特异性抗体阳性情况。
结果肺癌、肝癌、口腔癌、宫颈癌和白血病患者的血清抗弓形虫IgG抗体阳性率分别为21.46%、25.68%、25.22%、21.56%和19.44%，均显著高于健康对照组的4.33%（χ²分别为41.67、55.85、39.89、40.09和28.55，P值均 < 0.01），抗弓形虫IgM抗体阳性率的差异均无统计学意义（校正χ²分别为0.00、0.07、0.05、0.04和0.01，P值均>0.05）。5种不同类型恶性肿瘤患者抗弓形虫IgG和IgM抗体阳性率的差异均无统计学意义（χ²=3.98、0.65，P值均>0.05）。男性和女性肺癌、肝癌、口腔癌和白血病患者抗弓形虫IgG抗体阳性率的差异均无统计学意义（P值均>0.05），不同年龄组、不同居住地和不同民族5种恶性肿瘤患者抗弓形虫IgG抗体阳性率的差异均无统计学意义（P值均>0.05）。
结论恶性肿瘤患者的抗弓形虫IgG抗体阳性率显著高于健康对照者，但不同类型恶性肿瘤患者弓形虫特异性抗体阳性率的差异均无统计学意义。不同类型恶性肿瘤患者血清抗弓形虫IgG抗体阳性率不具有性别、年龄、居住地和民族特异性。今后应加强恶性肿瘤患者弓形虫感染筛查，防止弓形虫病造成的危害。

Abstract:
ObjectiveTo compare the status of Toxoplasma gondii(T.gondii) infections among patients with various types of malignant tumors, so as to provide insights into the prevention and control of T.gondii infections among cancer patients in Hangzhou.
MethodsA total of 410 lung cancer patients, 370 liver cancer patients, 115 oral cancer patients, 320 cervical cancer patients and 180 leukemia patients undergoing treatment in Yuhang District First Hospital of Hanghzou City from 2012 to 2019 were enrolled as the test subjects, and 300 healthy volunteers that were randomly selected from the Physical Examination Center of Yuhang District First Hospital served as controls.The serum IgG and IgM antibodies against T.gondii were detected using enzyme-linked immunosorbent assay (ELISA) in all study subjects, and the seroprevalence of anti-T.gondii antibodies was compared among patients with various types of cancers, and among cancer patients with various demographic characteristics.
ResultsThe seroprevalence of anti-T.gondii IgG antibody was 21.46%, 25.68%, 25.22%, 21.56% and 19.44% in patients with lung cancer, liver cancer, oral cancer, cervical cancer and leukemia, which was all significantly greater than in healthy controls (4.33%) (χ²=41.67, 55.85, 39.89, 40.09 and 28.55, all P values < 0.01); however, no significant differences were found between cancer patients and healthy controls (adjusted χ²=0.00, 0.07, 0.05, 0.04 and 0.01, all P values >0.05).There was no cancer type-specific seroprevalence of anti-T.gondii IgG and IgM antibodies (χ²=3.98 and 0.65, both P values >0.05).There were no significant differences in the seroprevalence of anti-T.gondii IgG antibody between male and female patients with lung, liver, oral cancer and leukemia (all P values >0.05).In addition, there were no age-, residency-and ethnicity-specific seroprevalence of anti-T.gondii IgG antibody among patients with the 5 types of malignant tumors (all P values >0.05).
ConclusionThe cancer patients present with significantly higher seroprevalence of anti-T.gondii IgG antibody than healthy controls, however, there are no cancer type-specific seroprevalence of anti-T.gondii antibody.In addition, there is no gender-, age-, residency-or ethnicity-specific seroprevalence of anti-T.gondii antibody in cancer patients.Screening of T.gondii infections is strongly recommended to prevent the damages caused by toxoplasmosis.

HTML全文

参考文献(20)

施引文献

资源附件(0)